Physicians tend to underestimate both stroke and bleeding risk when deciding whether or not to treat atrial fibrillation (AF) patients with oral anticoagulants. An analysis published online March 29 in Circulation found that in up to 80 percent of cases, physician-assessed risk differed from objective risk scores.

Cardiologists whose patients are not good candidates for dual antiplatelet therapy (DAPT) may have an option beyond a bare metal stent. Results from a trial presented March 31 at the American College of Cardiology (ACC) scientific session in Washington, D.C., showed that treatment with a drug-eluting stent (DES) in combination with a personalized DAPT approach appeared to be safe and effective at one year.

The FDA approved dabigatran for the treatment of deep vein thrombosis and pulmonary embolism in certain patients.

The association between aortic valve replacements (AVR) and clinical strokes may be stronger than originally believed, data from a study published April 1 in Circulation suggest.

Medtronic indicated that the company is willing to support another renal denervation trial after seeing a glimmer of hope in subgroup analyses of patients with resistant hypertension. The lead investigator of the failed SYMPLICITY HTN-3 encouraged proponents to persevere, but with caution.

College football players tend to have stiffer arteries than other college students, even before their college athletic careers have started, cardiology researchers have found.

The Detroit Medical Center (DMC) is the first in the Midwest to use a new, state-of-the-art system for treating Coronary Artery Disease (CAD).

OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the COMBO Stent for the treatment of coronary lesions in the setting of routine clinical care. The registry enrolled 1,000 patients at nine European high-volume percutaneous coronary intervention centers in France, Latvia, Luxembourg, The Netherlands, United Kingdom and Spain.